Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etravirine - Janssen R&D Ireland

Next Previous
X
Search
Drug Profile

Etravirine - Janssen R&D Ireland

Alternative Names: Intelence; R165335; TMC-125

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen-Cilag; Xian-Janssen
  • Class Antiretrovirals; Pyridazines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Apr 2018 French National Institute for Health and Medical Research completes a phase II trial for HIV-1 infections (Combination therapy, Treatment-experienced) in France, and Spain (NCT02212379)
  • 10 Mar 2015 No recent reports on development identified - Phase-II for HIV-1 infections (Combination therapy, Treatment-naive) in USA, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Romania, Russia, Spain, Switzerland and United Kingdom (PO)
  • 16 Nov 2012 Committee for Medicinal Products for Human Use recommends approval of Etravirine for HIV-1 infections (combination therapy, in children, in adolescents, treatment-experienced patients) in EU

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top